OMDA Overview

Omada Health Inc Trading Update: Shares of Omada Health Inc (OMDA) have entered oversold territory with an RSI of 27.7, indicating potential exhaustion of recent selling pressure.

Current Share Price and Performance: The stock traded as low as $17.83, with a last trade at $18.17, while its 52-week range is between $14.14 and $28.40.

Comparison with S&P 500 ETF: The current RSI of the S&P 500 ETF (SPY) is 35.7, suggesting that OMDA's lower RSI may present a buying opportunity for bullish investors.

Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.

Event Participation: Omada Health will participate in the 8th Annual Evercore Healthcare Conference in Miami, featuring a fireside chat on December 3, 2025, at 1:20 pm ET, with a webcast available online.

Company Overview: Omada Health is a virtual healthcare provider focused on cardiometabolic conditions and musculoskeletal issues, utilizing a combination of human care teams, connected devices, and AI technology for personalized care.

Experience and Impact: With over a decade of experience, Omada has served more than one million members and has published 30 peer-reviewed studies demonstrating its clinical and economic effectiveness.

Recognition and Results: The company has received multiple healthcare accreditations and is recognized for its evidence-based approach that improves health outcomes while managing healthcare costs.

Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.

Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, fostering a collaborative environment for sharing market intelligence.

Market Success: The platform is designed to help traders win in the markets every day by providing accurate and immediate stock market intelligence.

Omada Health's New Offerings: Omada Health will begin prescribing GLP-1s and other obesity medications as part of its weight management program, which is expanding to over 800,000 members.

Market Potential: The digital health sector is increasingly entering the lucrative GLP-1 market, projected to be worth around $100 billion by the end of the decade, with companies like Eli Lilly and Novo Nordisk working to enhance accessibility.

Patient Support: Omada aims to provide comprehensive support for patients on GLP-1s, including medication management and lifestyle coaching, to help them navigate the complexities and side effects associated with these treatments.

Partnerships and Growth: The company collaborates with health plans and employers to enhance employee health while managing costs, and it recently reported its quarterly earnings following its IPO in June.